Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 6/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 5/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595879 | 1.00 | MARS2 (0.46) | MARS2PDE10AGRIA1KDM4EALDH1A1 | |
| SCHEMBL20595804 | 0.83 | MARS2 (0.49) | MARS2KDM4EALDH1A1MAPT | |
| SCHEMBL20595820 | 0.83 | MARS2 (0.54) | MARS2 | |
| SCHEMBL30145159 | 0.83 | MARS2 (0.54) | MARS2 | |
| SCHEMBL20595877 | 0.79 | MARS2 (0.52) | MARS2KDM4EALDH1A1MAPT | |
| SCHEMBL30145200 | 0.77 | MARS2 (0.57) | MARS2 | |
| SCHEMBL20596612 | 0.77 | MARS2 (0.57) | MARS2 | |
| SCHEMBL30145178 | 0.77 | MARS2 (0.62) | MARS2LMNA | |
| SCHEMBL20596061 | 0.77 | MARS2 (0.62) | MARS2LMNA | |
| SCHEMBL20596133 | 0.74 | MARS2 (0.52) | MARS2ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885PDE10A 4121/4885GRIA1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.